🌍📈🧬 #Epidemiology of #RenalCancer: #Incidence, #Mortality, #Survival, #GeneticPredisposition, and #RiskFactors https://t.co/YKFXuvZzP9 Up-to -date facts and figures together with future projections at @EUplatinum

Join our must-attend #UROwebinar, our 2nd one next week! Learn how digital technologies enhance efficiency, support clinical decision-making, and increase surgeon autonomy. Register now 👇 https://t.co/i8mID1WESV @_alelarcher @francesco_cei1 @marciomoschovas @pidebacker

#GURetreat25 @montypal #ccRCC: a lot of possible futures but now is the Microbiome Moment! #nccRCC: Finally dedicated data: KN B61…waiting for trials in horizon! @_alelarcher The key is also integration of data and techniques for patients with @KidneyCancer ! @AndreaNecchi

Terrific #prostatecancer lectures from @Albert0Briganti @SanRaffaeleMI & @neerajaiims @huntsmancancer, spanning #localized & #metastatic dz. Nice to see so much practice-informing data in Dr. Briganti’s journal, @EUplatinum. Appreciate @AndreaNecchi bringing us all together.

New Cheat Sheet: Advanced & metastatic RCC – key points on cytoreductive nephrectomy, metastasectomy, radiotherapy, embolisation, and systemic therapies. Covers patient selection, outcomes, and evolving IO/TKI strategies. #EAUguidelines Download: https://t.co/2QVxcpQoCq

😀😀😀I am very, very, very happy to share together with @Anto_cigliola the introduction of systemic therapy with #HIF inhibitors as part of our clinical and research program dedicated to people with #vonHippelLindau syndrome💊💊💊 Thrilling moment and key milestone for our

🗣️ Le parole di @_alelarcher dopo la vittoria del Premio Matula. #SIU25 #Urologia

Thrilled to share a great #multidisciplinary effort to advance #hereditaryRCC care! 🧬 A practical step-by-step guide bridging urology, oncology & genetics to help clinicians identify, counsel & manage patients with suspected #hereditaryRCC. @EAUYAU_RenalCa

Will we cross paths in your city soon? Together with national societies, the EAU will share vital updates shaping the field. Check out where we're off too next this month 👉 https://t.co/qkM4509BO7

⏳ È la settimana di #SIULIVE! 👩‍⚕️👨‍⚕️ Ti aspettiamo giovedì a Sorrento. #SIU25

Spotlight: Epidemiology of Renal Cancer: Incidence, Mortality, Survival, Genetic Predisposition, and Risk Factors by Alessandro Larcher et al #Spotlight #Medtwitter #UroSoMe #RenalCancer

👩‍⚕️Operatori top expert italiani e stranieri 🆕 Le tecniche più innovative 🔁 Combinazione di sessioni di chirurgia in diretta 🗣️ Dibattiti tra moderatori in auditorium 📝 Per partecipare basta essere iscritti al 98° Congresso Nazionale #SIU25. Scopri di più ➡️

⏳⏳⏳ 👩‍⚕️👨‍⚕️ Per partecipare è necessario essere iscritti al 98° Congresso Nazionale #SIU25. Scopri di più ➡️

A discussion for the record books. @AndreaNecchi provides an amazing overview of considerations (geographic variations in practice, treatment landscape, etc.). Beautiful figures done in collaboration w @NazliDizman, @BrigidaMaiorano et al. Bravo! #ESMO25

#RenalCancer #Epidemiology Update: #Incidence, #Mortality, #Survival, #GeneticPredisposition, and #RiskFactors • 🌍 434,840 cases and 11,953 deaths in 2022 • 📈 Incidence projected to increase by +72% by 2050 • 📈 Mortality projected to increase by +96% by 2050 • 📊

🔙 #SIULIVE inaugura il 98° Congresso Nazionale SIU con una nuova veste: torna in presenza e si trasforma in CONGRESS EDITION! 👩‍⚕️👨‍⚕️ I membri del Comitato Scientifico ti aspettano per un evento unico nel panorama urologico, con interventi in diretta eseguiti da esperti italiani e

👩‍⚕️👨‍⚕️ #SIULIVE torna in presenza! 🏥 Un evento unico in ambito urologico che presenta, in diretta, interventi di chirurgia urologica eseguiti “a casa propria” da colleghi italiani e stranieri. #Urologia

Proud to share our experience from the @SanRaffaeleMI #VHL Program assessing PROMs in VHL 🔑VHL patients show more depression than those with sporadic RCC 🧠Psychological support must be part of SoC for hereditary cancer syndromes! @VHLAlliance @JCOOA_ASCO https://t.co/NWkxD3m8jk

Lymphovascular Invasion in #kidneycancer increases risk of mortality in stage T1-T3a; impact = to upstaging by 1 stage. Data call for consideration of T1b/T2 for adjuvant therapy #clinicaltrials @kcCURE @KidneyCancer @EAU_Uroonco @MichaelStaehler https://t.co/Ug9fbsGNoE

🚨 New paper! 🔬 Biopsy-all strategy for renal masses vs ⚡ Immediate surgery Simulation results (1,729 pts): 6.7% surgeries avoided ↓ complications (−3%, −2.5% severe) 💰 $840 saved/patient 👉 https://t.co/66JXbom7nO Should biopsy be the new standard? @_alelarcher